scott runyon

Dr. scott runyon


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SNSanju Narayanan
Sanju Narayanan
DHDanni Harris
Danni Harris
RMRangan Maitra
Rangan Maitra
SRscott runyon
scott runyon

1 August 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SNSanju Narayanan
Sanju Narayanan
RMRangan Maitra
Rangan Maitra
JDJeffrey Deschamps
Jeffrey Deschamps
KBKatherine Bortoff
Katherine Bortoff
JTJames B. Thomas
James B. Thomas
SRscott runyon
scott runyon

1 July 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YZYanan Zhang
Yanan Zhang
BGBrian P. Gilmour
Brian P. Gilmour
HNHernán A. Navarro
Hernán A. Navarro
SRscott runyon
scott runyon

1 May 2017 in Neuropharmacology
Verified
Journal Article
Closed access
SCStewart D. Clark
Stewart D. Clark
TKTerrence P. Kenakin
Terrence P. Kenakin
SGSteven Gertz
Steven Gertz
CHCarla Hassler
Carla Hassler
EGElaine A. Gay
Elaine A. Gay
SRscott runyon
scott runyon

1 February 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SNSanju Narayanan
Sanju Narayanan
VVVineetha Vasukuttan
Vineetha Vasukuttan
SRSudarshan Rajagopal
Sudarshan Rajagopal
RMRangan Maitra
Rangan Maitra
SRscott runyon
scott runyon

25 June 2014 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
CHCarla Hassler
Carla Hassler
YZYanan Zhang
Yanan Zhang
BGBrian Gilmour
Brian Gilmour
TGTyler Graf
Tyler Graf
TFTimothy Raymond Fennell
Timothy Raymond Fennell
SRscott runyon
scott runyon
Modulation of the neuropeptide S (NPS) system has been linked to a variety of CNS disorders such as panic disorder, anxiety, sleeping disorders, asthma, obesity, PTSD, and substance abuse. In this study, a series of diphenyltetrahydro-1H-oxazolo[3,4-α]pyrazin-3(5H)-ones were synthesized and evaluated for antagonist activity at the neuropeptide S receptor. The absolute configuration was determined by chiral resolution of the key synthetic intermediate, followed by analysis of one of the individual enantiomers by X-ray crystallography. The R isomer was then converted to a biologically active compound (34) that had a Ke of 36 nM. The most potent compound displayed enhanced aqueous solubility compared with the prototypical antagonist SHA-68 and demonstrated favorable pharmacokinetic properties for behavioral assessment. In vivo analysis in mice indicated a significant blockade of NPS induced locomotor activity at an ip dose of 50 mg/kg. This suggests that analogs having improved drug-like properties will facilitate more detailed studies of the neuropeptide S receptor system.